In 2007, the company was selected as one of the "Top 0/00 Most Growing Science and Technology Enterprises in China" and won the "Shenzhen Science and Technology Innovation Award".

In 2008, it cooperated strategically with Softbank Safran Asia Investment Fund and Shenzhen Innovation Investment Group, realizing the "strong alliance" between famous domestic and foreign investment institutions and domestic polypeptide pharmaceutical industry; It was named "Top 50 High-tech and High-growth Enterprises of Deloitte in China in 2008" and won the titles of "Shenzhen Science and Technology Innovation Award" and "Shenzhen Leading Enterprise in Independent Innovation Industry".

In 2009, it won the titles of Zero2IPO-Top 50 Enterprises with the Most Investment Value, Leading Enterprise in Nanshan District, Shenzhen Famous Brand and National High-tech Enterprise.

20 10 was selected as "Top 200 Potential Enterprises in China" by Forbes magazine, ranking 59th.

On 20 1 1 year, the "Guangdong Polypeptide Drug Engineering Technology Research and Development Center" established by the company was recognized as "National Local Joint Engineering Laboratory" by the National Development and Reform Commission.